SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking.
Over the past 15 years, SCT has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). Mechanistic studies recently provided the proof-of-concept that restoration of immunological tolerance can be achieved by haematopoietic SCT in chronic autoimmunity through eradication of the pathologic, immunologic memory and profound reconfiguration of the immune system, that is, immune 'resetting'. Nevertheless, a number of areas remain unresolved and warrant further investigation to refine our understanding of the underlying mechanisms of action and to optimize clinical SCT protocols. Due to the low number of patients transplanted in each centre, it is essential to adequately collect and analyse biological samples in a larger cohort of patients under standardized conditions. The European society for blood and marrow transplantation Autoimmune Diseases and Immunobiology Working Parties have, therefore, undertaken a joint initiative to develop and implement guidelines for 'good laboratory practice' in relation to procurement, processing, storage and analysis of biological specimens for immune reconstitution studies in AD patients before, during and after SCT. The aim of this document is to provide practical recommendations for biobanking of samples and laboratory immune monitoring in patients with ADs undergoing SCT, both for routine supportive care purposes and investigational studies.
Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
T
T
Alexander
Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
A
A
Bondanza
Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK.
P A
PA
Muraro
Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
R
R
Greco
Cord Blood Bank, Haematology department, Careggi University Hospital, Florence, Italy.
R
R
Saccardi
Department of Rheumatology, University Hospital Basel, Basel, Switzerland.
T
T
Daikeler
Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
M
M
Kazmi
Nottingham Digestive Diseases Centre, Nottingham, UK.
C
C
Hawkey
Department of Clinical Medicine, School of Medicine, University of Sao Paulo, Ribeirao Preto, Brazil.
B P
BP
Simoes
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
K
K
Leblanc
Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands.
W E
WE
Fibbe
Department of Haematology, St Vincent's Hospital, Darlinghurst, Sydney, Australia.
J
J
Moore
Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
E
E
Snarski
Strasbourg University Hospital, Strasbourg, France.
T
T
Martin
Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
F
F
Hiepe
Department of Medicine, Division of Haematology, University of Perugia, Perugia, Italy.
A
A
Velardi
Inserm U1160, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Hôpital Saint-Louis, Laboratoire d'Immunologie, Paris, France.
A
A
Toubert
Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, Sheffield, UK.
J A
JA
Snowden
Saint Louis Hospital, Unité de Médecine interne et Pathologie Vasculaire, Assistance Publique des Hôpitaux de Paris, Paris 7 University, INSERM U1160, Paris, France.
D
D
Farge
D001327:Autoimmune Diseases / Q000628:therapy*; D018070:Biological Specimen Banks / Q000592:standards*; D003226:Congresses as Topic; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000592:standards; D006801:Humans; D017410:Practice Guidelines as Topic; D011309:Preservation, Biological / Q000592:standards*; D012720:Severity of Illness Index; D012955:Societies, Medical